Robert Sarkany, MD, FRCP, discusses PORT-77's phase 2a safety profile in EPP and the endpoints to watch as the drug advances to phase 2b/3.
Robert Sarkany, MD FRCP
Advertisement
Robert Sarkany, MD, FRCP, is a consultant dermatologist at St John's Institute of Dermatology at Guy's and St Thomas' Hospital in London and at the Lister Hospital.
Articles by Robert Sarkany, MD FRCP
In this interview, Robert Sarkany, MD, FRCP, explains the biology behind erythropoietic protoporphyria and how PORT-77 targets its underlying cause.
Recent phase 2a findings on PORT-77 show rapid, dose-dependent plasma PPIX reductions in erythropoietic protoporphyria and X-linked protoporphyria.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH
2
FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome
3
Zilurgisertib Receives FDA Approval for FOP in Patients 12 and Older
4
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
5